SMW Free Realtime Trade Alerts -- Fast Moving Stocks < $15 -- Join Today for FREE!!
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
Loading IDRA News...
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||-0.35%||78.97||1.1%||$778.95m|
|SRPT||Sarepta Therapeutics, Inc.||5.31%||62.24||27.0%||$475.37m|
|REGN||Regeneron Pharmaceuticals, Inc.||-0.56%||419.10||3.7%||$315.62m|
|ALXN||Alexion Pharmaceuticals, Inc.||-1.76%||123.76||2.2%||$173.50m|
|CLVS||Clovis Oncology, Inc.||-2.94%||36.34||28.4%||$163.46m|
|VRTX||Vertex Pharmaceuticals Incorporated||-0.31%||88.84||2.3%||$127.85m|
|BMRN||BioMarin Pharmaceutical Inc.||-1.05%||96.03||4.0%||$114.07m|
Idera Pharmaceuticals, Inc. is a clinical stage biotechnology company, which is engaged in discovery, development and commercialization of novel nucleic acid therapeutics to treat patients with serious and life-threatening diseases. Idera's immunotherapy approach is based on the modulation of toll-like receptors (TLRs) while its third-generation antisense technology is designed to inhibit the production of disease-associated proteins by targeting RNA. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal and James B. Wyngaarden in May 25, 1989 and is headquartered in Cambridge, MA.